| Title |
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
|
|---|---|
| Published in |
BioDrugs, November 2017
|
| DOI | 10.1007/s40259-017-0247-0 |
| Pubmed ID | |
| Authors |
Marco Ruella, Saad S. Kenderian |
| Abstract |
Autologous, patient-specific chimeric antigen receptor T-cell (CART) therapy has emerged as a powerful and potentially curative therapy for cancer, especially for CD19-positive hematological malignancies. Indeed, on August 30, 2017, the University of Pennsylvania-designed CD19-directed CART (CART-19) cell therapy (CTL019, tisagenlecleucel-t, Kymriah - Novartis) became the first CART therapy approved by the Food and Drug Administration (FDA) for acute lymphoblastic leukemia. However, the development of CART technology and its wider application is partly limited by the patient-specific nature of such a platform and by the time required for manufacturing. The efficacious generation of universal allogeneic CART cells would overcome these limitations and represent a major advance in the field. However, several obstacles in the generation of universal CART cells need to be overcome, namely the risk of CART rejection and the risk of graft-versus-host disease mediated by the allogeneic CART. In this review, we discuss the different strategies being employed to generate universal CART and provide our perspective on the successful development of a truly off-the-shelf CART product. |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 165 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 31 | 19% |
| Researcher | 24 | 15% |
| Student > Ph. D. Student | 23 | 14% |
| Student > Master | 13 | 8% |
| Student > Doctoral Student | 8 | 5% |
| Other | 13 | 8% |
| Unknown | 53 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 30 | 18% |
| Medicine and Dentistry | 18 | 11% |
| Immunology and Microbiology | 15 | 9% |
| Agricultural and Biological Sciences | 14 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 6% |
| Other | 22 | 13% |
| Unknown | 56 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2023.
All research outputs
#1,780,832
of 23,592,647 outputs
Outputs from BioDrugs
#34
of 681 outputs
Outputs of similar age
#33,574
of 295,483 outputs
Outputs of similar age from BioDrugs
#2
of 8 outputs
Altmetric has tracked 23,592,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 681 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,483 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.